Sanara MedTech (SMTI) Competitors

Sanara MedTech (NASDAQ:SMTI) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Which has more risk and volatility, SMTI or TNDM?

Sanara MedTech has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

Is SMTI or TNDM more profitable?

Sanara MedTech has a net margin of -10.22% compared to Tandem Diabetes Care's net margin of -20.51%. Sanara MedTech's return on equity of -25.92% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-10.22%	-25.92%	-10.92%
Tandem Diabetes Care	-20.51%	-65.40%	-13.87%

Does the media refer more to SMTI or TNDM?

In the previous week, Tandem Diabetes Care had 41 more articles in the media than Sanara MedTech. MarketBeat recorded 51 mentions for Tandem Diabetes Care and 10 mentions for Sanara MedTech. Tandem Diabetes Care's average media sentiment score of 0.79 beat Sanara MedTech's score of 0.27 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tandem Diabetes Care	23 Very Positive mention(s)	10 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of SMTI or TNDM?

8.1% of Sanara MedTech shares are held by institutional investors. 42.6% of Sanara MedTech shares are held by company insiders. Comparatively, 1.9% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend SMTI or TNDM?

Sanara MedTech currently has a consensus price target of $49.50, suggesting a potential upside of 62.83%. Tandem Diabetes Care has a consensus price target of $22.67, suggesting a potential upside of 112.63%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Which has better earnings and valuation, SMTI or TNDM?

Sanara MedTech has higher earnings, but lower revenue than Tandem Diabetes Care. Sanara MedTech is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$86.67M	3.12	-$9.66M	-$1.34	-22.69
Tandem Diabetes Care	$940.20M	0.77	-$96.03M	-$3.09	-3.45

Summary

Sanara MedTech beats Tandem Diabetes Care on 9 of the 16 factors compared between the two stocks.